Synthesis and Biological Evaluation of Benzimidazole Derivatives Targeting Neurodegeneration in Alzheimer’s Disease
Abstract
Alzheimer's disease (AD) is the most prevalent dementia and continues to be a significant public health problem due to its irreversible, progressive and multifactorial pathogenesis. Existing treatment options, such as acetylcholinesterase inhibitors and memantine, are only partially effective in preventing the death of neurons. Due to the complex interplay of accumulation of Amyloid-β, hyperphosphorylation of tau, dysfunction of cholinergic systems, oxidative stress, mitochondrial dysfunction, and neuroinflammation, MTDLs (multitarget-directed ligands) are needed. Benzimidazole is a privileged neurotherapeutic scaffold that possesses drug-like properties, has structural versatility and can have multiple interactions with AD associated targets. In the present work, novel substituted benzimidazole derivatives were designed in a rational manner, synthesized, characterized and evaluated for their biological activities to develop multifunctional anti-Alzheimer agents. The design approach involves a combination of pharmacophore-based modelling, structure–activity relationship (SAR) analysis and optimization of drug-likeness for central nervous system (CNS) penetration. Structural modifications at the C2, N1 and benzene ring positions, linker optimization, are investigated for improving cholinesterase inhibition, anti-amyloidogenic activity, antioxidant activity and anti-neuroinflammatory activity. Biological evaluation consists of AChE and BChE inhibition by Ellman's method, anti-Aβ aggregation by Thioflavin-T fluorescence assay, fibril morphology analysis with TEM/AFM, and anti-neuroinflammatory activity by measuring the levels of TNF-α, IL-6, IL-1β and NF-κB signaling in LPS stimulated BV-2 microglial cells. Evaluation of the integrated strategy will likely lead to the discovery of new, promising lead compounds with dual blood–brain barrier permeability and poly-functional neuroprotective activity that may provide a rational approach to the development of disease-modifying drugs for AD.